Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 84Breast Neoplasms 34Colorectal Neoplasms 26Lung Neoplasms 23Rectal Neoplasms 22Neoplasms 21Esophageal Squamous Cell Carcinoma 20Neoplasm Metastasis 19Esophageal Neoplasms 19Head and Neck Neoplasms 17Stomach Neoplasms 15Pancreatic Neoplasms 15Squamous Cell Carcinoma of Head and Neck 14Triple Negative Breast Neoplasms 12Small Cell Lung Carcinoma 12Ovarian Neoplasms 11Recurrence 10Nasopharyngeal Carcinoma 10Carcinoma, Squamous Cell 10Uterine Cervical Neoplasms 9Leukemia, Myeloid, Acute 9Colonic Neoplasms 9Glioblastoma 8Prostatic Neoplasms 7Lymphoma, Large B-Cell, Diffuse 7Lymphoma 7Sarcoma 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Melanoma 6Lymphoma, Non-Hodgkin 6

Interventions

pyrotinib 1Drug Therapy 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × HER2 Positive Metastatic Breast Cancer × Drug Therapy × Clear all
NCT04681287 2023-09-25

Exploratory Study of Advanced Breast Cancer in HER2 Positive Patients With Failure of Multi-line Therapy Treated by Combination of Inetetamab (Cipterbin) + PD-1 Inhibitor Combined With Utidelone.

Henan Cancer Hospital

Phase 2 Unknown
46 enrolled
Breast

HER2 Positive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡